Synspire Pharmaceuticals Presents Data at 34rd Annual North American Cystic Fibrosis Conference on Effect of SNSP113 on Recalcitrant Methicillin Resistant Staphylococcus aureus (MRSA) Posted on October 23, 2020May 8, 2023 by Kathryn Kilroy Continue reading “Synspire Pharmaceuticals Presents Data at 34rd Annual North American Cystic Fibrosis Conference on Effect of SNSP113 on Recalcitrant Methicillin Resistant Staphylococcus aureus (MRSA)”
Synspire Pharmaceuticals Presents Data on Effect of SNSP113 on Chronic, Recalcitrant Nontuberculosis Mycobacteria (NTM) Pulmonary Infections at 33rd Annual North American Cystic Fibrosis Society Conference Posted on October 31, 2019May 8, 2023 by Kathryn Kilroy Continue reading “Synspire Pharmaceuticals Presents Data on Effect of SNSP113 on Chronic, Recalcitrant Nontuberculosis Mycobacteria (NTM) Pulmonary Infections at 33rd Annual North American Cystic Fibrosis Society Conference”
Synspire Pharmaceuticals Presents Data at 42nd Annual European Cystic Fibrosis Society Conference on Effect of SNSP113 on nontuberculosis Mycobacteria and Burkholderia Pulmonary Infections Posted on June 7, 2019May 8, 2023 by Kathryn Kilroy Continue reading “Synspire Pharmaceuticals Presents Data at 42nd Annual European Cystic Fibrosis Society Conference on Effect of SNSP113 on nontuberculosis Mycobacteria and Burkholderia Pulmonary Infections”
Synspire Pharmaceuticals SNSP 113 Demonstrates Improvement in Abnormal Cystic Fibrosis Mucus and Pulmonary Disease Posted on April 23, 2019May 9, 2023 by Kathryn Kilroy Continue reading “Synspire Pharmaceuticals SNSP 113 Demonstrates Improvement in Abnormal Cystic Fibrosis Mucus and Pulmonary Disease”
Synspire Pharmaceuticals Receives Orphan Designation for SNSP113 for the Treatment of Cystic Fibrosis in the European Union Posted on April 10, 2019May 10, 2023 by Kathryn Kilroy Continue reading “Synspire Pharmaceuticals Receives Orphan Designation for SNSP113 for the Treatment of Cystic Fibrosis in the European Union”
Synspire Pharmaceuticals Announces Abstracts Evaluating New Treatment Options for Cystic Fibrosis Complications Accepted for Presentation at the 32nd Annual North American Cystic Fibrosis Conference Posted on October 12, 2018May 10, 2023 by Kathryn Kilroy Continue reading “Synspire Pharmaceuticals Announces Abstracts Evaluating New Treatment Options for Cystic Fibrosis Complications Accepted for Presentation at the 32nd Annual North American Cystic Fibrosis Conference”
Synspire Pharmaceuticals Receives U.S. FDA Orphan Designation for SNSP113 for the Treatment of Cystic Fibrosis Posted on October 11, 2018May 10, 2023 by Kathryn Kilroy Continue reading “Synspire Pharmaceuticals Receives U.S. FDA Orphan Designation for SNSP113 for the Treatment of Cystic Fibrosis”
Synspire Pharmaceuticals PAAG Therapy Demonstrates Persistence Against Pseudomonas aeruginosa Persister Cells Posted on August 9, 2018May 10, 2023 by Kathryn Kilroy Continue reading “Synspire Pharmaceuticals PAAG Therapy Demonstrates Persistence Against Pseudomonas aeruginosa Persister Cells”
Synspire Pharmaceuticals Novel Glycopolymer Proves Effective Against Antibiotic Resistance Posted on January 17, 2018May 10, 2023 by Kathryn Kilroy Continue reading “Synspire Pharmaceuticals Novel Glycopolymer Proves Effective Against Antibiotic Resistance”
Synspire Pharmaceuticals Announces Data for Lead Candidate at the 31st Annual North American Cystic Fibrosis Conference Posted on November 2, 2017May 10, 2023 by Kathryn Kilroy Continue reading “Synspire Pharmaceuticals Announces Data for Lead Candidate at the 31st Annual North American Cystic Fibrosis Conference”
Toggle navigation
Toggle navigation